A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Elismetrep (Primary)
- Indications Diabetic neuropathies; Neurological disorders; Vasomotor symptoms
- Focus Adverse reactions
- Acronyms MT-8554 DQT
- Sponsors Mitsubishi Tanabe Pharma America
- 05 Nov 2018 Status changed from recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
- 12 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.